Study suggests anti-amyloid treatment may halve
Author: Michael
Elevant’s best-selling biohacking product prov
Company to initiate clinical study of gene-silen
Sens.
Portuguese defender invests more than €1 milli
Longevity startup offers AI-powered blood biomar
New research finds that endothelial TDP-43 loss
Progress in spinal cord injury lays the foundati
London is the setting for the next edition of a
Immorta Bio is developing autologous stem cell a